KDventures has completed a directed share issue of class B shares and, at the same time, finalized the acquisition of Rosetta Capital IV Sàrl’s holding in KDev Investments AB. In connection with this,...
Published
KDventures has completed a directed issue of 99,516,667 B shares at SEK 0.24 per share, raising approximately SEK 23.9 million to finance the acquisition of Rosetta Capital IV Sàrl's shares in KDev Investments...
Published
Global pharmaceutical company funds Phase 3 studies with tafoxiparin.
Published
Comment by: Viktor Drvota
“The study is continuing according to plan, and our assessment is that the round should cover the remaining requirements needed to complete the study and generate data.”
Published
The portfolio company is carrying out a directed share issue of SEK 19.6 million, as part of a larger share issue estimated at SEK 64 million.
Published
KDventures participated in Redeye's event Next Gen Healthcare on May 26. The presentation was held by Chief Legal Officer and Deputy CEO Johan Dighed.
Published
Watch KDventure's CEO Victor Drvota present the company's investment strategy and answer questions.
Published
2025 was filled with progress in clinical development and strategic collaborations across our portfolio companies. During the latter part of the year, we laid the groundwork for the financing round that...
Published
KDventures reported the outcome of the rights issue after the subscription period ended on 27 January 2026.
Published
New data show that more than half of PBC patients suffer from severe fatigue or cognitive symptoms – highlighting the need for new therapies.
Published
Modus Therapeutics strengthens its financial position and focuses on the Phase IIa study with sevuparin. KDventures subscribed for its share in the TO2 warrant programme.
Published
Positive data from the GOAL-HF1 Phase 1b/2a study were presented on May 11, 2026 at the ESC Heart Failure Association Congress 2026 in Barcelona. The session is reserved for studies of high scientific...
Published
Here you can find annual reports, interim reports, year-end reports and presentations from capital markets days.
